Judging from the position structure, the key varieties allocated by Gulen Medical Fund belong to the white horse stocks in the original medical industry.
Such key medical enterprises benefited from the overall loose monetary environment after the epidemic and the market's pursuit of high-growth stocks. However, after the Federal Reserve released the expectation of raising interest rates, the growth stocks represented by the Nasdaq index have already encountered great callback pressure.
In the A-share market, growth stocks such as photovoltaic, new energy vehicles, lithium batteries and biomedicine, which were originally popular tracks, all showed obvious pullbacks. At the same time, some white horse stocks in the domestic medical industry have also encountered the unilateral "black hand" of the United States.
This price correction may decrease with the release of the valuation bubble of individual stocks, but during the Fed's interest rate hike cycle, the rising resistance of medical stocks is still great.
Therefore, the macro environment does not support the "rapid turnover" of medical funds.